Imperva (IMPV) Raised to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Imperva (NASDAQ:IMPV) from a sell rating to a hold rating in a report released on Tuesday.
According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “
Several other research firms also recently commented on IMPV. Stifel Nicolaus dropped their price objective on Imperva from $50.00 to $48.00 and set a buy rating on the stock in a research note on Friday, July 27th. Evercore ISI reiterated a buy rating and issued a $56.00 price objective on shares of Imperva in a research note on Friday, July 27th. Royal Bank of Canada reiterated a buy rating and issued a $62.00 price objective on shares of Imperva in a research note on Friday, July 27th. UBS Group downgraded Imperva from an outperform rating to a market perform rating in a research note on Friday, July 27th. Finally, Oppenheimer downgraded Imperva from an outperform rating to a market perform rating and set a $70.00 price objective on the stock. in a research note on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $54.00.
Imperva (NASDAQ:IMPV) last posted its quarterly earnings data on Thursday, July 26th. The software maker reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. Imperva had a negative return on equity of 6.92% and a negative net margin of 8.59%. The business had revenue of $84.80 million for the quarter, compared to the consensus estimate of $87.22 million. During the same quarter in the prior year, the business earned $0.24 earnings per share. Imperva’s revenue for the quarter was up 13.9% on a year-over-year basis. equities analysts anticipate that Imperva will post -1.15 earnings per share for the current year.
Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in Imperva by 276.2% during the 1st quarter. Russell Investments Group Ltd. now owns 2,588 shares of the software maker’s stock valued at $112,000 after acquiring an additional 1,900 shares during the period. Royal Bank of Canada raised its holdings in Imperva by 99.4% during the 1st quarter. Royal Bank of Canada now owns 2,794 shares of the software maker’s stock valued at $122,000 after acquiring an additional 1,393 shares during the period. Aperio Group LLC bought a new stake in Imperva during the 2nd quarter valued at $203,000. Xact Kapitalforvaltning AB bought a new stake in Imperva during the 1st quarter valued at $205,000. Finally, Oppenheimer & Co. Inc. bought a new stake in Imperva during the 2nd quarter valued at $222,000.
Imperva Company Profile
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.